ALSO NOTED: Eisai withdraws European Aricept application; FDA approves GSK's Altabax; and much more...

> Japan's Eisai has withdrawn its European application for Aricept as a treatment for Alzheimer's after regulators asked for more data. Report

> Novelos Therapeutics is planning a $15 million private placement. Release

> The FDA has approved GlaxoSmithKline's antibacterial Altabax. Report

> India's Lupin Pharmaceuticals has received FDA approval for a new formulation of its anti-infective Suprax. Release

> Alkermes announced that the FDA has approved a new dose of risperidone for schizophrenia. Report

And Finally... Indian officials are on alert after an outbreaK of bird flu in Bangladesh. Report

Suggested Articles

Merck’s TIGIT-blocking prospect and PD-1 med Keytruda shrank tumors in 29% of lung cancer patients who had never tried a checkpoint inhibitor.

Merck's HIF-2α inhibitor, picked up in its $1 billion Peloton buyout, shrank kidney tumors in 36% of patients and showed promise in other tumors, too.

Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice.